- Sputnik International, 1920
World
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

Russia in Talks With Several Austrian Companies on Sputnik V Production, RDIF CEO Says

© REUTERS / AGUSTIN MARCARIANA shipment of doses of the Sputnik V (Gam-COVID-Vac) vaccine against the coronavirus disease (COVID-19)
A shipment of doses of the Sputnik V (Gam-COVID-Vac) vaccine against the coronavirus disease (COVID-19)  - Sputnik International, 1920, 20.02.2021
Subscribe
VIENNA (Sputnik) - Moscow is negotiating with several Austrian companies to set up production of Russian coronavirus vaccine Sputnik V in this country, Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said on Saturday.
"Austria has some of the best companies in the world for the production of pharmaceuticals. We are already in negotiations with several Austrian companies. We would like to have a partnership with Austria for the production and, among other things, for the export of this vaccine from Austria to other countries", he said on the air of Austrian broadcaster Ö1.

Dmitriev did not indicate with which Austrian firms the negotiations were underway.

Apart from Austria, Moscow sees support for the Sputnik V vaccine from Germany, France and Italy, Dmitriev added.

"Politicians in these countries say that people should have a right to choose a vaccine," Dmitriev said adding that politics is not involved in the vaccine in any manner.

A health worker holds the Russian coronavirus vaccine Gam-COVID-Vac, trade-named Sputnik V, developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology during the vaccination of medical workers, in Sestroretsk, Leningrad region, Russia - Sputnik International, 1920, 04.11.2020
Russia
Russia Ready to Cooperate on Sputnik V Vaccine on Platform of Council of Europe, Lavrov Says
The Russian vaccine, developed by the Gamaleya Epidemiology and Microbiology Centre and registered by the Russian Ministry of Health on 11 August, was the world's first registered vaccine against the coronavirus.

In February, peer-reviewed medical journal The Lancet published an interim analysis from Phase III clinical trial of the Russian vaccine, showing its 91.6-percent efficacy against symptomatic COVID-19. The vaccine has already been approved in 30 countries, including Belarus, Serbia, Hungary, San Marino, Argentina, Bolivia, Mexico, Nicaragua, Algeria, Lebanon and the United Arab Emirates, among others.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала